Cronos Group Inc. income statement
In fiscal 2025, Cronos Group Inc. reported revenue of $147m, up 24.6% on the year before, operating income of −$17.4m (a -11.9% margin) and net income of −$9.4m, or −$0.02 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 12 | 24 | 47 | 65 | 87 | 87 | 118 | 147 | 179 |
| Gross profit | 2 | 6 | −18 | −26 | −18 | 15 | 12 | 25 | 63 | 82 |
| Research and development | 0 | 2 | 12 | 20 | 22 | 13 | 6 | 4 | 4 | 5 |
| Selling and marketing | 0 | 3 | 23 | 34 | 21 | 18 | 23 | 22 | 22 | 24 |
| General and administrative | 5 | 13 | 81 | 81 | 91 | 68 | 49 | 47 | 42 | 45 |
| Operating income | −6 | −20 | −153 | −219 | −292 | −111 | −85 | −77 | −17 | −2 |
| Interest expense | 0 | 0 | 1 | 0 | 0 | 0 | — | — | — | — |
| Provision for credit losses | — | 0 | 0 | 2 | 12 | −1 | −2 | −11 | 5 | — |
| Income before tax | −2 | −21 | 1,166 | −73 | −129 | −121 | −74 | 37 | −17 | 68 |
| Income tax | −1 | 0 | 0 | 1 | −0 | 34 | −3 | −3 | −14 | −11 |
| Net income | −1 | −22 | 1,167 | −73 | −396 | −169 | −74 | 41 | −9 | 70 |
| Diluted EPS | −$0.01 | −$0.06 | $3.33 | −$0.21 | −$1.07 | −$0.45 | −$0.19 | $0.11 | −$0.02 | $0.18 |
| Diluted shares (average) | 354m | 345m | 343m | 352m | 370m | 377m | 381m | 386m | 383m | 380m |
| EBITDA | −5 | −19 | −149 | −212 | −277 | −98 | −77 | −67 | −3 | 6 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34 | 30 | 32 | 33 | 36 | 45 | 45 | 53 |
| Gross profit | 4 | 11 | 14 | 15 | 18 | 16 | 19 | 28 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Selling and marketing | 6 | 6 | 5 | 5 | 5 | 7 | 6 | 7 |
| General and administrative | 13 | 12 | 9 | 11 | 9 | 13 | 12 | 11 |
| Operating income | −34 | −11 | −4 | −5 | −1 | −7 | −2 | 7 |
| Provision for credit losses | −12 | 0 | 0 | — | — | — | — | — |
| Income before tax | 5 | 46 | 7 | −39 | 27 | −12 | 18 | 36 |
| Income tax | −3 | 2 | −0 | −1 | −1 | −12 | 2 | 0 |
| Net income | 8 | 44 | 6 | −40 | 26 | −2 | 14 | 32 |
| Diluted EPS | $0.02 | $0.12 | $0.02 | −$0.10 | $0.07 | $0.00 | $0.04 | $0.09 |
| EBITDA | −33 | −9 | −1 | −4 | −0 | −4 | 2 | 8 |
Compare with peers
- Kamada LTD income statement
- Amarin Corp plc\uk income statement
- Biote Corp. income statement
- Organigram Global Inc. income statement
- Heron Therapeutics, Inc. income statement
Head to head: CRON vs KMDAAMRN vs CRONBTMD vs CRONCRON vs OGI
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies